The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution

Post hoc analysis of sustained efficacy/tolerability of ≥12 cycles of omacetaxine mepesuccinate in chronic myeloid leukemia (CML).

Delphine Rea

Honoraria - Bristol-Myers Squibb; Novartis; Teva

Hagop M. Kantarjian

Research Funding - ARIAD; Bristol-Myers Squibb; Bristol-Myers Squibb; ChemGenex; Novartis; Novartis; Pfizer; Pfizer

Meir Wetzler

Consultant or Advisory Role - Teva

Research Funding - Bristol-Myers Squibb

Franck E. Nicolini

Consultant or Advisory Role - ARIAD; Novartis

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva

Research Funding - Novartis

Jeffrey H. Lipton

Consultant or Advisory Role - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva

Stock Ownership - ARIAD

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Pfizer; Teva

Luke Paul Akard

Consultant or Advisory Role - Bristol-Myers Squibb; Eisai; Millennium; Novartis; Teva

Honoraria - ARIAD; Bristol-Myers Squibb; Novartis; Teva

Research Funding - ARIAD; Bristol-Myers Squibb; Novartis; Teva

Hanna Jean Khoury